Patent or Trade Secret in Israel? Choosing the Right Protection

The choice between patent protection and trade secret protection is not simply a question of which right is stronger. They operate differently. A patent can give its owner, for a limited period, the right to prevent others from exploiting the patented invention even if they developed it independently. A trade secret does not confer a monopoly over information: protection depends on maintaining secrecy and does not prevent another business from reaching the same knowledge through independent development or lawful reverse engineering.

For a company developing technology in Israel, or foreign counsel advising on Israeli intellectual property rights, the central question is therefore not only whether an invention can be patented. It is what will happen to the information after the product reaches the market, whether it can realistically remain confidential over time and which right can be enforced effectively against competitors.

What can be protected by a patent in Israel?

Under Israel’s Patents Law, 5727-1967, a product or process in a field of technology may qualify for patent protection if it is new, useful, capable of industrial application and involves an inventive step. Not all business or technical information meets those requirements.

Trade secrets can cover a wider range of information. They may include formulas, manufacturing processes and engineering know-how, but also source code, experimental data, operational methods, manufacturing parameters, pricing models and commercial information that would not qualify for a patent at all. The conditions for protection are discussed in our guide, What Qualifies as a Trade Secret in Israel?

Where technology may satisfy the patentability requirements, there may be a genuine choice between these forms of protection. Where the information cannot qualify for a patent, protection, if available, will generally depend on trade secret law, contractual obligations and effective confidentiality measures.

Can competitors discover the technology by examining the product?

This is one of the most important practical considerations.

Suppose a competitor can buy the product after launch, disassemble or test it, and determine how the technology works. In that situation, keeping the technology as a trade secret may offer limited protection. Section 6(c) of Israel’s Commercial Torts Law, 5759-1999, provides that discovery through reverse engineering does not, by itself, constitute an improper means of obtaining a trade secret. If a competitor lawfully discovers the technology, the trade secret owner generally cannot prevent its use merely because the same information was previously confidential.

A patent may provide a significant advantage in that situation. Subject to its valid claims and the applicable legal limitations, it can prevent the exploitation of the invention even where a competitor arrived at the technology independently or worked it out from a lawfully marketed product.

The analysis is different when the protected technology consists of an internal process that cannot be learned from the finished product, a manufacturing formula that cannot be deduced from the product, a proprietary calibration system, process parameters or an algorithm operating in a closed environment. Maintaining such information as a trade secret may be a realistic alternative.

As Deutsch explains in his discussion of trade secret protection, choosing secrecy means accepting protection that is not monopolistic and bearing the risk of independent discovery or reverse engineering. Patent protection provides a stronger right against independent competitors, but requires disclosure of the invention.

The price of patent protection is disclosure

A patent application cannot merely state a general technological idea. Section 12 of the Israeli Patents Law requires a specification that describes how the invention can be performed so that a person skilled in the art can carry it out.

As a general rule, an Israeli patent application is published 18 months after the relevant priority date or the filing date in Israel. Once the application is published, the information it discloses can no longer remain a trade secret.

This is the underlying exchange: the applicant discloses the invention to the public and, if the legal requirements are satisfied, receives an exclusive right of limited duration. Filing an application simply to see whether it will succeed, without accounting for future publication, may therefore be a costly strategic mistake. If the application is later refused or the patent invalidated, information already made public does not become secret again.

Disclosure obligations do not, however, require a company to publish every item of know-how it possesses. It may sometimes be possible to patent a technological principle while maintaining supplementary information in confidence, such as optimal operating parameters, manufacturing techniques, calibration data or practical implementation know-how. The essential qualification is that the withheld information must not be material that the patent specification is required to disclose to enable the skilled person to perform the claimed invention.

Protection against independent development

This may be the most important legal distinction between the two approaches.

If two companies independently develop the same invention, the holder of a valid patent may be able to prevent the other company from exploiting it, subject to the patent claims and other provisions of applicable law. A trade secret owner cannot do so merely because another party has produced the same solution. Trade secret law addresses prohibited acquisition, use or receipt of protected information, not the existence of a competing product developed without misuse of that information.

The distinction matters in industries where competing research teams are likely to solve the same technical problem. When the problem is apparent, the market is competitive and several businesses are working towards a similar solution, independent development may be a substantial risk.

Patentability requirements are the other side of this stronger protection. Developing a solution independently is not sufficient; the invention must still meet the requirements of novelty and inventive step. In Merck Sharp & Dohme Corp. v. Teva Pharmaceutical Industries Ltd., Tel Aviv District Court, Case 45243-09-19 (3 December 2021), the court examined those requirements in the context of a pharmaceutical invention.

How long does each form of protection last?

Under Section 52 of the Israeli Patents Law, the ordinary patent term is 20 years from the application date, subject to special statutory extension arrangements applicable to certain categories of patents.

Trade secrets have no predetermined statutory term. Information may remain protected as long as it continues to be secret, derives commercial value from its secrecy and is protected through reasonable measures. This may be an important advantage where confidential technology can retain its value for a period longer than the possible patent term.

Secrecy is not guaranteed, however. An employee may leave, an information system may be compromised, a supplier may breach its obligations, or a competitor may develop the information independently or discover it through lawful reverse engineering.

The Coca-Cola example

The Coca-Cola formula is a familiar example of a trade secret strategy. The company describes its beverage formulas as important trade secrets, and according to its own account of the formula’s history, the formula has been kept confidential since the drink was invented in 1886.

This does not establish that trade secret protection is generally preferable to patents. It illustrates circumstances in which information has been kept confidential for a period far exceeding the possible term of a patent. Deutsch uses this example to explain why the holder of valuable information might accept the risk of eventual disclosure instead of securing a right that expires after a fixed period.

The same strategy would be less effective for technology that can readily be understood from the product itself. If a formula, process or technical structure becomes apparent through ordinary examination of a marketed product, the practical advantage of maintaining it as a trade secret is significantly reduced.

Can the business actually preserve confidentiality?

Choosing trade secret protection has little value unless the organization can keep the relevant information confidential.

The business must control access, know who possesses the information, limit disclosure to those who need it, regulate permitted use through contracts and apply appropriate technical and organizational safeguards. Where information is provided to investors, manufacturers, subcontractors or commercial partners, confidentiality and the recipient’s permissible uses should be addressed before disclosure. Our guide to non-disclosure agreements in Israel explains the contractual aspect.

The danger is not hypothetical. In Gmida v. Fisher, Tel Aviv District Court, Civil Case 2117/07 (5 December 2012), confidential business information was transferred through a former employee who accessed the company’s computer systems. The case illustrates a structural weakness of trade secret protection: its value depends in part on preventing information from leaving the owner’s control.

Which right will be easier to enforce?

Even after a legal strategy is selected, the business must consider whether infringement or misappropriation will be detectable and provable.

Where a competitor’s product is sold openly, it may be possible to inspect the product and determine whether it falls within the claims of a patent. By contrast, a patent covering a manufacturing process performed entirely inside a competitor’s factory may be more difficult to enforce if there is no practical way to establish how the process is carried out.

In such circumstances, maintaining the process as a trade secret may have advantages, provided that confidentiality can realistically be preserved. The issue is not simply which right appears stronger in legal terms, but which mechanism can be maintained and enforced in the commercial circumstances of the particular technology.

Costs and territorial scope

Patents are territorial rights. A business seeking protection in multiple markets must plan a filing strategy and bear the costs of applications, examination, translations, official fees and ongoing maintenance in the relevant jurisdictions. Foreign businesses seeking patent protection in Israel can find further information in our Israeli patent prosecution practice.

A trade secret does not require separate registration in each country, but maintaining confidentiality has other costs: information security, contracts, access management, employee and supplier procedures, and legal action if protected information is disclosed. The legal scope of trade secret protection may also differ between the jurisdictions in which the company operates.

Can patents and trade secrets be combined?

The choice is not always binary.

A company may patent the technological core that is visible in the product, or that competitors are likely to develop independently, while retaining supplementary know-how that does not have to be disclosed in the application. The patent can protect the claimed technical principle while confidential implementation information provides a further commercial advantage.

The boundary is set by patent disclosure requirements. A company cannot validly secure patent protection for an invention while withholding material information that is legally necessary to enable a skilled person to carry it out.

When should a company favor a patent, and when a trade secret?

Patent protection generally warrants serious consideration where the invention will become apparent after the product is launched, can readily be reverse engineered, may be developed independently by competitors, or where licensing and investment are likely to depend on a clearly defined registered right.

Trade secret protection may be more appropriate where the information concerns an internal process that is difficult to discover externally, can remain confidential within the organization over time, may retain commercial value beyond the possible patent term, or is not patentable in the first place.

Before making the decision, the company should preserve both options. Publicly disclosing an invention before filing a patent application may undermine novelty, while disclosing confidential information may destroy its status as a trade secret. The protection strategy should therefore be decided before the technology is made public, not afterwards.

Have a question about the article?

You might also be interested in